Psgl-1 Deficiency is Protective against Stroke in a Murine Model of Lupus

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Hui ^a   Knight, Jason S ^b   Hodgin, Jeffrey B ^b   Wang, Jintao ^a   Guo, Chiao ^a   Kleiman, Kyle ^a   Eitzman, Daniel T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTACOID; MEMBRANE PROTEIN; P-SELECTIN LIGAND PROTEIN; PRISTANE; TERPENE;

ANIMAL; BLOOD; BRAIN; C57BL MOUSE; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DISEASE MODEL; FEMALE; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION MEDIATORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; SPECIFIC PATHOGEN-FREE ORGANISMS; STROKE; TERPENES;

EID: 84977100873     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28997     Document Type: Article

References (25)

1. Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145, 408-415 (1997).
2. Ward, M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42, 338-346, doi: 10.1002/1529-0131(199902)42:2<338::AID-ANR17> 3.0.CO;2-U (1999).
3. Krishnan, E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med 118, 1415, doi: 10.1016/j. amjmed.2005.05.026 (2005).
4. Futrell, N. & Millikan, C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 20, 583-591 (1989).
5. Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349, 2399-2406, doi: 10.1056/NEJMoa035471 (2003).
6. Esdaile, J. M. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44, 2331-2337 (2001).
7. Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 187, 538-552, doi: 10.4049/jimmunol.1100450 (2011).
8. Knight, J. S. et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest 123, 2981-2993, doi: 10.1172/JCI67390 (2013).
9. Zarbock, A., Ley, K., McEver, R. P. & Hidalgo, A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 118, 6743-6751, doi: 10.1182/blood-2011-07-343566 (2011).
10. Summers, S. A. et al. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun 35, 291-298, doi: 10.1016/j.jaut.2010.05.004 (2010).
11. Savarese, E. et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 58, 1107-1115, doi: 10.1002/art.23407 (2008).
12. Wang, J. et al. mTOR Inhibition Improves Anaemia and Reduces Organ Damage in a Murine Model of Sickle Cell Disease. Br J Haematol, doi: 10.1111/bjh.14057 (2016).
13. Su, E. J. et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14, 731-737, doi: 10.1038/nm1787 (2008).
14. Kienhofer, D. et al. No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis. PLoS One 9, e115474, doi: 10.1371/journal.pone.0115474 (2014).
15. Han, S. et al. Maintenance of autoantibody production in pristane-induced murine lupus. Arthritis research & therapy 17, 384, doi: 10.1186/s13075-015-0886-9 (2015).
16. He, X. et al. Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J Immunol 177, 8748-8756 (2006).
17. Summers, S. A. et al. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. Clin Exp Immunol 176, 341-350, doi: 10.1111/cei.12287 (2014).
18. Liu, C. et al. Targeted IgA Fc receptor I (FcalphaRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice. Clin Exp Immunol 181, 407-416, doi: 10.1111/cei.12647 (2015).
19. Crispin, J. C. et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in molecular medicine 16, 47-57, doi: 10.1016/j.molmed.2009.12.005 (2010).
20. Fleming, S. D., Monestier, M. & Tsokos, G. C. Accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. J Immunol 173, 4230-4235 (2004).
21. Timlin, H. & Petri, M. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus 22, 1251-1258, doi: 10.1177/0961203313497416 (2013).
22. James, W. G., Bullard, D. C. & Hickey, M. J. Critical role of the alpha 4 integrin/VCAM-1 pathway in cerebral leukocyte trafficking in lupus-prone MRL/fas(lpr) mice. J Immunol 170, 520-527 (2003).
23. Egerer, K. et al. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 9, 614-621 (2000).
24. Luo, W. et al. Increased stroke size following MCA occlusion in a mouse model of sickle cell disease. Blood 123, 1965-1967, doi: 10.1182/blood-2014-01-549717 (2014).
25. Sorce, S. et al. Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5. Br J Pharmacol 160, 311-321, doi: 10.1111/j.1476-5381.2010.00697.x (2010).